Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate

Markus Joerger(Kantonsspital St. Gallen), Alwin D. R. Huitema(The Netherlands Cancer Institute), Thomas Cerny(University Hospital Bonn), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Emanuele Zucca(Università della Svizzera italiana), Stephan Krähenbühl(University Hospital of Basel), Jan H.M. Schellens(Utrecht University)
British Journal of Clinical Pharmacology
August 12, 2011
10.1111/j.1365-2125.2011.04084.x
Cited by 36

Related Papers

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451